Literature DB >> 710967

Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high permeability membrane.

J Denis, P Opolon, V Nusinovici, A Granger, F Darnis.   

Abstract

Forty-one patients with fulminant hepatic failure and coma underwent 180 periods of haemodialysis with polyacrylonitrile membrane (AN 69 HD). Hepatic failure was due to viral hepatitis in 40 and drugs in one. Total recovery of consciousness occurred in 17 patients (43.6%), and partial in seven (17.9%)--that is, an overall figure of 61.5%. Regain of consciousness was not related to liver regeneration as assessed by levels of factor V and hepatocyte volume fraction. At the time of the first haemodialysis, neurological status was significantly impaired in the patients who could not be aroused. Mean duration of coma grade IV averaged 6.1 +/- 4.3 days and mean duration of illness until death or decerebration 8.6 +/- 8.3 days. Of the 17 patients who totally regained consciousness, nine recovered and eight died (three from intercurrent complications and five with no liver regeneration).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 710967      PMCID: PMC1412181          DOI: 10.1136/gut.19.9.787

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  25 in total

1.  Effect of insulin and glucagon on fulminant murine hepatitis.

Authors:  M Farivar; J R Wands; K J Isselbacher; N L Bucher
Journal:  N Engl J Med       Date:  1976-12-30       Impact factor: 91.245

2.  Reversible modifications of neurotransmitters of the brain in experimental acute hepatic coma.

Authors:  P Bloch; M L Delorme; J R Rapin; A Granger; M Boschat; P Opolon
Journal:  Surg Gynecol Obstet       Date:  1978-04

Review 3.  Acute hepatic necrosis and fulminant hepatic failure.

Authors:  B Rueff; J P Benhamou
Journal:  Gut       Date:  1973-10       Impact factor: 23.059

4.  Charcoal haemoperfusion in the treatment of fulminant hepatic failure.

Authors:  B G Gazzard; M J Weston; I M Murray-Lyon; H Flax; C O Record; R Williams; B Portmann; P G Langley; E H Dunlop; P J Mellon; M B Ward
Journal:  Lancet       Date:  1974-06-29       Impact factor: 79.321

5.  Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis.

Authors:  D B Silk; P N Trewby; R A Chase; P J Mellon; M A Hanid; M Davies; P G Langley; P G Wheeler; R Williams
Journal:  Lancet       Date:  1977-07-02       Impact factor: 79.321

6.  Experiences in the treatment of fulminant hepatic failure by conservative therapy, charcoal haemoperfusion, and polyacrylonitrile haemodialysis.

Authors:  D B Silk; R Williams
Journal:  Int J Artif Organs       Date:  1978-01       Impact factor: 1.595

7.  [Fulminant hepatitis: an experience based on 137 cases. I. Complications (author's transl)].

Authors:  V Nusinovici; C Crubille; P Opolon; J P Touboul; F Darnis; J Caroli
Journal:  Gastroenterol Clin Biol       Date:  1977

8.  [Fulminant hepatitis: an experience based on 137 cases. II. Course and prognosis].

Authors:  V Nusinovici; C Crubille; P Opolon; J P Touboul; F Darnis; J Caroli
Journal:  Gastroenterol Clin Biol       Date:  1977

9.  Plasma and brain amino acids in fulminant hepatic failure and their relationship to hepatic encephalopathy.

Authors:  C O Record; B Buxton; R A Chase; G Curzon; I M Murray-Lyon; R Williams
Journal:  Eur J Clin Invest       Date:  1976-09-10       Impact factor: 4.686

10.  Plasma amino acid patterns in hepatic encephalopathy of differing etiology.

Authors:  H M Rosen; N Yoshimura; J M Hodgman; J E Fischer
Journal:  Gastroenterology       Date:  1977-03       Impact factor: 22.682

View more
  13 in total

Review 1.  Extracorporeal perfusion for the treatment of acute liver failure.

Authors:  H B Stockmann; C A Hiemstra; R L Marquet; J N IJzermans
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

2.  Liver support in acute liver failure.

Authors:  Robin D Hughes
Journal:  Wien Klin Wochenschr       Date:  2003-09-15       Impact factor: 1.704

Review 3.  Artificial and bioartificial support systems for liver failure.

Authors:  J P Liu; L L Gluud; B Als-Nielsen; C Gluud
Journal:  Cochrane Database Syst Rev       Date:  2004

4.  A bioartificial liver to treat severe acute liver failure.

Authors:  J Rozga; L Podesta; E LePage; E Morsiani; A D Moscioni; A Hoffman; L Sher; F Villamil; G Woolf; M McGrath
Journal:  Ann Surg       Date:  1994-05       Impact factor: 12.969

5.  Postoperative liver insufficiency: prevention and management.

Authors:  H Bismuth; D Houssin; G Mazmanian
Journal:  World J Surg       Date:  1983-07       Impact factor: 3.352

6.  Fulminant hepatic failure in childhood.

Authors: 
Journal:  Br Med J       Date:  1980-09-27

7.  Fulminant hepatic failure in childhood: an analysis of 31 cases.

Authors:  H T Psacharopoulos; A P Mowat; M Davies; B Portmann; D B Silk; R Williams
Journal:  Arch Dis Child       Date:  1980-04       Impact factor: 3.791

8.  Development of a hybrid bioartificial liver.

Authors:  J Rozga; M D Holzman; M S Ro; D W Griffin; D F Neuzil; T Giorgio; A D Moscioni; A A Demetriou
Journal:  Ann Surg       Date:  1993-05       Impact factor: 12.969

9.  Prognostic value of hepatic volumetry in fulminant hepatic failure.

Authors:  K Sekiyama; M Yoshiba; K Inoue; F Sugata
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

10.  Successful treatment of refractory cerebral oedema in ecstasy/cocaine-induced fulminant hepatic failure using a new high-efficacy liver detoxification device (FPSA-Prometheus).

Authors:  Ludwig Kramer; Edith Bauer; Peter Schenk; Rudolf Steininger; Marion Vigl; Reinhold Mallek
Journal:  Wien Klin Wochenschr       Date:  2003-09-15       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.